Literature DB >> 35395151

Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.

Pauline Vetter1,2,3, Isabella Eckerle4,5,6, Benjamin Meyer7, Olha Puhach8, Kenneth Adea8, Nicolas Hulo9, Pascale Sattonnet8, Camille Genecand10, Anne Iten11, Frédérique Jacquérioz12,13,14, Laurent Kaiser12,15,16.   

Abstract

Infectious viral load (VL) expelled as droplets and aerosols by infected individuals partly determines transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). RNA VL measured by qRT-PCR is only a weak proxy for infectiousness. Studies on the kinetics of infectious VL are important to understand the mechanisms behind the different transmissibility of SARS-CoV-2 variants and the effect of vaccination on transmission, which allows guidance of public health measures. In this study, we quantified infectious VL in individuals infected with SARS-CoV-2 during the first five symptomatic days by in vitro culturability assay in unvaccinated or vaccinated individuals infected with pre-variant of concern (pre-VOC) SARS-CoV-2, Delta or Omicron BA.1. Unvaccinated individuals infected with pre-VOC SARS-CoV-2 had lower infectious VL than Delta-infected unvaccinated individuals. Full vaccination (defined as >2 weeks after receipt of the second dose during the primary vaccination series) significantly reduced infectious VL for Delta breakthrough cases compared to unvaccinated individuals. For Omicron BA.1 breakthrough cases, reduced infectious VL was observed only in boosted but not in fully vaccinated individuals compared to unvaccinated individuals. In addition, infectious VL was lower in fully vaccinated Omicron BA.1-infected individuals compared to fully vaccinated Delta-infected individuals, suggesting that mechanisms other than increased infectious VL contribute to the high infectiousness of SARS-CoV-2 Omicron BA.1. Our findings indicate that vaccines may lower transmission risk and, therefore, have a public health benefit beyond the individual protection from severe disease.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Year:  2022        PMID: 35395151     DOI: 10.1038/s41591-022-01816-0

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   87.241


  52 in total

Review 1.  Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences.

Authors:  Reem Hoteit; Hadi M Yassine
Journal:  Vaccines (Basel)       Date:  2022-06-09

2.  Early introduction and rise of the Omicron SARS-CoV-2 variant in highly vaccinated university populations.

Authors:  Brittany A Petros; Jacquelyn Turcinovic; Nicole L Welch; Laura F White; Eric D Kolaczyk; Matthew R Bauer; Michael Cleary; Sabrina T Dobbins; Lynn Doucette-Stamm; Mitch Gore; Parvathy Nair; Tien G Nguyen; Scott Rose; Bradford P Taylor; Daniel Tsang; Erik Wendlandt; Michele Hope; Judy T Platt; Karen R Jacobson; Tara Bouton; Seyho Yune; Jared R Auclair; Lena Landaverde; Catherine M Klapperich; Davidson H Hamer; William P Hanage; Bronwyn L MacInnis; Pardis C Sabeti; John H Connor; Michael Springer
Journal:  Clin Infect Dis       Date:  2022-05-25       Impact factor: 20.999

3.  Duration of COVID-19 PCR positivity for Omicron vs earlier variants.

Authors:  N Kojima; A Roshani; J D Klausner
Journal:  J Clin Virol Plus       Date:  2022-05-21

4.  Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers.

Authors:  Steven A Kemp; Mark T K Cheng; William L Hamilton; Kimia Kamelian; Sujit Singh; Partha Rakshit; Anurag Agrawal; Christopher J R Illingworth; Ravindra K Gupta
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

5.  Biofunctionalization of Graphene-Based FET Sensors through Heterobifunctional Nanoscaffolds: Technology Validation toward Rapid COVID-19 Diagnostics and Monitoring.

Authors:  Esteban Piccinini; Gonzalo E Fenoy; Agustín L Cantillo; Juan A Allegretto; Juliana Scotto; José M Piccinini; Waldemar A Marmisollé; Omar Azzaroni
Journal:  Adv Mater Interfaces       Date:  2022-03-18       Impact factor: 6.389

Review 6.  SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant.

Authors:  Eric A Meyerowitz; Aaron Richterman
Journal:  Infect Dis Clin North Am       Date:  2022-02-01       Impact factor: 5.905

7.  Impaired detection of omicron by SARS-CoV-2 rapid antigen tests.

Authors:  Andreas Osterman; Irina Badell; Elif Basara; Marcel Stern; Fabian Kriesel; Marwa Eletreby; Gamze Naz Öztan; Melanie Huber; Hanna Autenrieth; Ricarda Knabe; Patricia M Späth; Maximilian Muenchhoff; Alexander Graf; Stefan Krebs; Helmut Blum; Jürgen Durner; Ludwig Czibere; Christopher Dächert; Lars Kaderali; Hanna-Mari Baldauf; Oliver T Keppler
Journal:  Med Microbiol Immunol       Date:  2022-02-20       Impact factor: 4.148

8.  Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges.

Authors:  Evropi Amanatidou; Anna Gkiouliava; Eva Pella; Maria Serafidi; Dimitrios Tsilingiris; Natalia G Vallianou; Irene Karampela; Maria Dalamaga
Journal:  Metabol Open       Date:  2022-03-17

9.  Higher vaccination rates predict reduction in SARS-CoV-2 transmission across the United States.

Authors:  Jacky Au
Journal:  Infection       Date:  2022-03-22       Impact factor: 7.455

10.  Detection of the Omicron variant of SARS-CoV-2 in international travelers returning to Venezuela.

Authors:  Rossana C Jaspe; Yoneira Sulbaran; Carmen L Loureiro; Zoila C Moros; Ernestina Marulanda; Francis Bracho; Nieves A Ramírez; Yeilis Canonico; Pierina D'Angelo; Lieska Rodríguez; Julio Castro; Ferdinando Liprandi; Héctor R Rangel; Flor H Pujol
Journal:  Travel Med Infect Dis       Date:  2022-04-05       Impact factor: 20.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.